Navigation Links
Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals
Date:2/9/2009

rted total revenue to be flat. We anticipate that cash instrument sales in the current economic climate will slow, compared with the robust growth of cash instrument sales in the first half of 2008. However, solid recurring revenue growth is expected to continue," Garrett said.

"Operating margin is anticipated to be between 11.7% and 12%, after absorbing a significant currency head wind and a $25 million increase in pension expense. We are committed to zero overhead growth resulting in flat operating expense. At current exchange rates, non-operating expense should be around $22 million, due to expected gains on hedging contracts. Based on an estimated tax rate of 26% to 27% and a flat share count, earnings per fully diluted share should be between $3.85 and $4.05. The planned pacing of earnings growth is uneven, with as much as 65% of net earnings expected to come in the second half of the year, due to slowed growth of cash instrument sales and currency shifts in the first half. Capital expenditures are expected to be $350 to $375 million, and depreciation and amortization should be between $270 and $290 million.

"2009 will, no doubt, be a challenging year. However, we began to adjust our spend rate last summer when the U.S. Dollar strengthened dramatically. We believe we have identified and begun to implement changes necessary to deliver on our commitments. Solid trending of recurring revenue and positive cost management initiatives implemented in 2008 give us confidence that our 2009 goals are achievable," Garrett concluded.

Investor Conference Call

As previously announced, there will be a conference call today, Monday, February 9, 2009 at 5:00 pm ET to discuss the fourth quarter and full year ended December 31, 2008 results. The call will also be webcast live. The call is accessible to all investors through Beckman Coulter's website at

SOURCE Beckman Coulter - IR
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
9. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Newswire-FirstCall/ - Microbix Biosystems Inc. (th...the Form 52-109F1 Certification of Annual Filings ... James Long, the Chief Financial Officer (the "Off...nnection with the annual audited financial stateme...he Company initially filed the annual financial st...
(Date:11/6/2009)..., November 6 EUCODIS Bioscience, a...nd marketing enzymes for the,chemical industry ann...greement with Bio Sidus, the leading biopharmaceut...ement gives EUCODIS Bioscience exclusive access - ...us, proprietary collection of,psychrophilic bacter...
(Date:11/6/2009)...v. 6 Intarcia Therapeutics, Inc. d...DUROS® continuous delivery of exenatide) prog...nth Annual Diabetes Technology Meeting in San Fran...i-bin/prnh/20050301/SFTU126LOGO ) ,, Continuo... Lowers Plasma Glucose, HbA1c and Reduces Weight i...
(Date:11/5/2009)...Nov. 5 The endangered black-footed...U.S. This rare carnivore feeds on prairie dogs. ...nd often entire population die-offs in towns occur...implemented a ferret breeding program and has been...merly native habitat. Unfortunately, plague can s...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2
...ensive and,coherent corporate brand and positionin...place is a critical step to developing a pipeline ..., developing, retaining and,engaging top talent du...top,of mind for executives across the country toda...rategic HR topics at the,10th Annual Human Resourc...
...d tropic HIV patients with sa... Pathway Diagnostics announces,nationwide availabi...ensiTrop(TM) II assay, combining the sensitivity o...nology with the specificity of molecular,sequencin...f HIV infected,patients. Pathway performs the Sens...
..., May 7, 2008 at 10:00 AM EDT, CEDAR KNOLLS, N.J....IS ) today announced its financial results for,the...ill host a conference call to discuss first quarte...A live Webcast of the conference,call can be acces....emisphere.com .,The live conference call dial-in ...
Other Biology Technology:Group Hotel Rate Ends Friday: Reserve Now for Leadership Development Conference June 4-6 2Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay 2Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 2Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 3Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 4Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 5Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 6Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 7
(Date:11/4/2009)... (top news in natural science) , United States...s less water today than it did 35 years ago, despi...ater use are partly attributable to alternative co...rrigation systems. According to the latest USGS wa...he United States goes to cooling thermoelectric po...
(Date:11/4/2009)..., MO, November 4, 2009 Childhood obesity in the U...h more than one fourth of advertising on daytime a...rages and continuing questions about the role tele...ecember issue of the Journal of Nutrition Educati...ed at children might be a large contributor to the...
(Date:11/4/2009)...pore laboratory that deciphered the DNA codes, or ...phant shark, has joined The Genome 10K Project, an...itory of DNA sequences on 10,000 species of animal...at currently can not be achieved. , Participatin...published in the Nov. 5, 2009 issue of the Journa...
Breaking Biology News(10 mins):USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Forest Laboratories Announces Positive Top line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community acquired Bacteria 49495 1Forest Laboratories Announces Positive Top line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community acquired Bacteria 49495 2Forest Laboratories Announces Positive Top line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community acquired Bacteria 49495 3Forest Laboratories Announces Positive Top line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community acquired Bacteria 49495 4Forest Laboratories Announces Positive Top line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community acquired Bacteria 49495 5GEN reports on alternative feedstocks for ethanol production 8929 1Athletes spectators faced unprecedented air pollution at 2008 Olympic Games 8927 1Athletes spectators faced unprecedented air pollution at 2008 Olympic Games 8927 2Athletes spectators faced unprecedented air pollution at 2008 Olympic Games 8927 3
...lif. A research team led by Mark Hoddle , a biol...rly eradicated the glassy-winged sharpshooter , a...i and several other French Polynesian islands in t...ression, the researchers used biological control, ...rol and can be applied to areas where the sharpsho...
...Ill., March 13, 2008 Data published today in The ...l of a fully bioabsorbable drug eluting stent for ...ated no stent thrombosis, no clinically driven tar...iseased lesion), and a low (3.3 percent) rate of m...out to one year. These one year results for Abbott...
...tention deficit hyperactivity disorder stand a sub...ders in adolescence than girls without ADHD, a new...requently develop body-image dissatisfaction and m... purging behaviors that are common in bulimia nerv...ri Yee Mikami, who led the study. , The findings ...
Other Biology News:UCR-led research team uses tiny wasp to wipe out major agricultural pest in Tahiti 2UCR-led research team uses tiny wasp to wipe out major agricultural pest in Tahiti 3UCR-led research team uses tiny wasp to wipe out major agricultural pest in Tahiti 4The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent 2Adolescent girls with ADHD are at increased risk for eating disorders, study shows 2
ICC Diluent Buffer from BD Biosciences Pharmingen
Anti-J Chain Monoclonal Antibody, Unconjugated, Clone M19/9J from CHEMICON
ZOOM® IEF Fractionator from Invitrogen
Tissue Stat from Biomeda Corporation
Biology Products: